VCRE (61) NRIX (42) MBX (44) ZLAB (26) ⌘ Pro Terminal →

Viridian Therapeutics Inc. (VRDN) — RQD Stock Rating Cockpit

$24.80 +2.18% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $24.85

Viridian Therapeutics Inc. (VRDN) carries a Roarable Rating of D (Sell) with 45/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (45/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $2.81B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $24.85 (+0.20%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (45/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.3% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-5.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for VRDN)Realized 20D OHLCV Swing Band: ±10.2%

Deterministic 5-Pillar Attribution (45/100 Composite)

🔍 WHY VRDN SCORES 45/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+13/20 pts (29% of score)

20D Institutional Volume Accumulation (±10.2% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+12/20 pts (27% of score)

FRED Regime × Technicals: 55% of 52W Range • RSI-14 at 69.8 (BULLISH MOMENTUM)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$18.66+2% Next Q

Q2 (-2Q)

Grade D$19.03+17.6% Next Q

Q3 (-1Q)

Grade D$22.37+10.9% Next Q

Current

Grade D$24.80-6.3% Hist 90D α

Trajectory: E (37) → D (45)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a VRDN Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While VRDN currently carries a cautious 45/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($21.66) and Max Pain ($26.04) forces dealer call-delta covering toward $36.00.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $VRDN• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “VRDN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 45%NO 55%Trade / Inspect Odds →

RSI-14 MOMENTUMBULLISH MOMENTUM

69.830 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

2 / 99-Pt Accounting

52-WEEK LASER RANGE55% OF RANGE

L: $13$24.80H: $34

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 7 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 16 / 40

3. Hidden Risks & Market Weather● WATCH

SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: D+RQD 22 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on VRDN

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (35)

-35.0% ROIC with 42.0% gross margin and -9.85% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (50)

Altman-Z 4.20 and Piotroski 2/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (47)

16/40 institutional & smart-money positioning score with 12/20 macro alignment.

Bull Case: Why Buyers Like VRDN

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring VRDN)

✓Walkthrough of VRDN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

VRDN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +83.98%📐 HORIZONTAL RANGE

2026-10-30O $24.77H $25.00L $24.14C $24.80VOL 1.71M

RES: $30.52SUP: $17.60SMA50: $21.66SMA200: $21.76

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

VRDN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 VRDN Butterfly Map → + Track VRDN →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on VRDN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for VRDN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for VRDN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (VRDN)

Health Care Rank #470 of 1016 ⚔️ VCRE vs VRDN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (VRDN vs. VCRE, NRIX, MBX, ZLAB)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Viridian Therapeutics Inc. (VRDN) ranks #470 by composite RQD confidence (45/100, grade D) and #213 by equity capitalization ($2.81B). Within this direct 5-issuer industry benchmark cohort, VRDN leads on earnings valuation at N/A trailing P/E, while MBX leads on capital efficiency and profitability with -26.4% ROIC and — gross margin. VCRE currently holds the highest overall quantitative score in the immediate peer group at 61/100 (C-) compared with VRDN at 45/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
VRDN ACTIVE Viridian Therapeutics Inc.	D	45/100	—	—	-35.0%	+2.18%	$2.81B	Benchmark Subject
VCRE Vicore Pharma Holding AB	C-	61/100	—	—	—	+4.56%	$2.87B	/vcre-vs-vrdn →
NRIX Nurix Therapeutics Inc.	D-	42/100	—	—	-35.0%	-0.51%	$2.96B	/nrix-vs-vrdn →
MBX MBX Biosciences Inc.	D	44/100	—	—	-26.4%	+0.70%	$2.63B	/mbx-vs-vrdn →
ZLAB Zai Lab Limited	E	26/100	—	58.3%	-35.0%	-2.95%	$2.51B	/zlab-vs-vrdn →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001590750

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Viridian Therapeutics Inc. (VRDN) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$342.6M, operating cash flow of -$276.4M, and free cash flow of -$276.9M (-18.9% YoY). On the balance sheet, VRDN closed FY2025 with $899.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$342.6M	-$276.4M	-$276.9M	$899.4M	—
FY2024 (FY)	2024-12-31	$0	-$269.9M	-$232.3M	-$232.8M	$742.4M	$20.6M
FY2023 (FY)	2023-12-31	$0	-$237.7M	-$184.2M	-$184.2M	—	—

3. VRDN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is VRDN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Viridian Therapeutics Inc. (NASDAQ: VRDN) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $24.80 (+2.18% 1D, market cap $2.81B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, VRDN ranks #470 in composite RQD confidence.

How does VRDN compare to VCRE and NRIX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), VRDN carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, VCRE (Vicore Pharma Holding AB) holds a C- grade (61/100 RQD, P/E N/A, ROIC —, cap $2.87B) and NRIX (Nurix Therapeutics Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $2.96B). Among the 5-stock peer group, VRDN leads on earnings multiple (N/A) while MBX leads on capital efficiency (-26.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for VRDN?

Per VRDN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001590750), Viridian Therapeutics Inc. generated $0 in revenue, -$342.6M in net income, and -$276.9M in free cash flow against $899.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is VRDN trading relative to its 50-day, 200-day, and 52-week technical levels?

VRDN last traded at $24.80 (+2.18% on volume of 1,907,043 shares), positioning the stock +14.50% above its 50-day simple moving average ($21.66) and +13.97% above its 200-day simple moving average ($21.76). Across its 52-week range of $13.18 to $34.29, VRDN sits at the 55.0% percentile with a 14-day RSI of 69.8 (BULLISH MOMENTUM) and an implied next-earnings move of ±10.2% ($22.27 to $27.33).

VRDN Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell VRDN stock right now?

Viridian Therapeutics Inc. (VRDN) currently earns a Roarable Rating of D (Sell — SELL) with 45/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is VRDN's 12-month price target and RQD AI Jury consensus?

VRDN's 12-month base price target is $23.35 (range $18.21 to $36), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: VRDN RQD Cockpit VRDN 12M Forecast VRDN Earnings & Move VRDN Dividends & DRIP VRDN Insiders & 13F VRDN Whale Options VRDN Profit Sankey VRDN News & Why